BERGENBIO ASABERGENBIO ASABERGENBIO ASA

BERGENBIO ASA

No trades
See on Supercharts

BGBIO fundamentals

Key facts

Market capitalization
Founded
CEO
Website
About

BerGenBio ASA engages in the development of biopharmaceutical product for cancer therapy. It focuses on developing a pipeline of AXL kinase inhibitors. Its lead product bemcentinib, is a selective and orally bio-available small molecule AXL inhibitor. The company was founded by James Bradley Lorens and David R. Micklem on December 21, 2007 and is headquartered in Bergen, Norway.

Valuation

Fundamental metrics to determine fair value of the stock

Summary
No data available
There's currently no market capitalization, revenue or net income data to show.
Valuation ratios

Growth and Profitability

Company’s recent performance and margins

Dividends

Dividend yield, history and sustainability

No dividends
BGBIO has never paid dividends and has no current plans to do so.

Financial health

Financial position and solvency of the company